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Abstract
Background
Seasonal malaria chemoprevention (SMC) is now widely deployed in the Sahel, including
several countries that are major contributors to the global burden of malaria. Consequently,
it is important to understand whether SMC continues to provide a high level of protection
and how SMC might be improved. SMC was evaluated using data from a large, household-
randomised trial in Hounde´, Burkina Faso and Bougouni, Mali.
Methods and findings
The parent trial evaluated monthly SMC plus either azithromycin (AZ) or placebo, adminis-
tered as directly observed therapy 4 times per year between August and November (2014–
2016). In July 2014, 19,578 children aged 3–59 months were randomised by household to
study group. Children who remained within the age range 3–59 months in August each year,
plus children born into study households or who moved into the study area, received study
drugs in 2015 and 2016. These analyses focus on the approximately 10,000 children (5,000
per country) under observation each year in the SMC plus placebo group. Despite high
coverage and high adherence to SMC, the incidence of hospitalisations or deaths due to
malaria and uncomplicated clinical malaria remained high in the study areas (overall inci-
dence rates 12.5 [95% confidence interval (CI): 11.2, 14.1] and 871.1 [95% CI: 852.3,
890.6] cases per 1,000 person-years, respectively) and peaked in July each year, before
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SMC delivery began in August. The incidence rate ratio comparing SMC within the past 28
days with SMC more than 35 days ago—adjusted for age, country, and household cluster-
ing—was 0.13 (95% CI: 0.08, 0.20), P < 0.001 for malaria hospitalisations and deaths from
malaria and 0.21 (95% CI 0.20, 0.23), P < 0.001 for uncomplicated malaria, indicating pro-
tective efficacy of 87.4% (95% CI: 79.6%, 92.2%) and 78.3% (95% CI: 76.8%, 79.6%),
respectively. The prevalence of malaria parasitaemia at weekly surveys during the rainy
season and at the end of the transmission season was several times higher in children who
missed the SMC course preceding the survey contact, and the smallest prevalence ratio
observed was 2.98 (95% CI: 1.95, 4.54), P < 0.001. The frequency of molecular markers
of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance did not increase
markedly over the study period either amongst study children or amongst school-age chil-
dren resident in the study areas. After 3 years of SMC deployment, the day 28 PCR-unad-
justed adequate clinical and parasitological response rate of the SP + AQ regimen in
children with asymptomatic malaria was 98.3% (95% CI: 88.6%, 99.8%) in Burkina Faso
and 96.1% (95% CI: 91.5%, 98.2%) in Mali. Key limitations of this study are the potential
overdiagnosis of uncomplicated malaria by rapid diagnostic tests and the potential for resid-
ual confounding from factors related to adherence to the monthly SMC schedule.
Conclusion
Despite strong evidence that SMC is providing a high level of protection, the burden of
malaria remains substantial in the 2 study areas. These results emphasise the need for
continuing support of SMC programmes. A fifth monthly SMC course is needed to ade-
quately cover the whole transmission season in the study areas and in settings with similar
epidemiology.
Trial registration
The AZ-SMC trial in which these data were collected was registered at clinicaltrials.gov:
NCT02211729.
Author summary
Why was this study done?
• Seasonal malaria chemoprevention (SMC) is recommended for children under 5 years
of age in countries of the Sahel and sub-Sahel. Many countries in West and Central
Africa now have large-scale SMC programmes.
• The malaria burden remains high in several countries that have introduced SMC,
including Burkina Faso and Mali, which are amongst the most important contributors
to the global burden of malaria cases and deaths.
• It is important to understand whether SMC retains a high level of protection in these
areas and how its impact might be improved.
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What did the researchers do and find?
• In this study, the level of protection provided by SMC was investigated using data from
a large but closely supervised clinical trial in 2 districts in southern Burkina Faso and
Mali.
• SMC was delivered 4 times per year over 3 years, reaching a very high percentage of chil-
dren. All the daily doses of SMC were supervised by the study team. Specific substudies
showed that molecular markers of resistance to the combination of antimalarials used
for SMC were rare amongst malaria parasites and that the SMC combination was highly
effective in curing infections detected at the end of the rainy season.
• Malaria incidence was markedly reduced in the period immediately after each SMC
course. In the first 4 weeks after SMC, malaria cases were reduced by 78%, and malaria
hospitalisations and deaths from malaria were reduced by 87%.
• Despite the benefits of SMC, the number of malaria cases, hospital admissions for
malaria, and deaths from malaria remained very high in the study areas. There was a
large peak in July each year, coinciding with the beginning of the rainy season, before
SMC delivery began in August.
What do these findings mean?
• SMC is likely to be averting a very large number of malaria cases, hospitalisations, and
deaths in the study areas, but malaria has still not been brought under control.
• At least one additional monthly course of SMC is needed to address the high burden of
malaria, including malaria deaths, that currently occurs outside the peak transmission
season. This is likely to be the case in other areas of the Sahel that have a longer trans-
mission season than can be covered by a 4-month SMC programme.
• Additional new tools are needed urgently to further reduce malaria in these districts
and areas with similar epidemiology.
Introduction
Seasonal malaria chemoprevention (SMC) comprises monthly courses of sulfadoxine-pyri-
methamine plus amodiaquine (SP + AQ) given to children 3–59 months of age. After encour-
aging results from trials in a range of settings, including in the context of high coverage of
long-lasting insecticide-treated nets (LLINs) [1,2], SMC became a WHO policy in 2012 for the
prevention of malaria in areas of seasonal transmission [3,4], and it is now implemented
widely in the Sahel and sub-Sahelian regions of Africa [5]. The current WHO recommenda-
tion specifies that SMC can be administered up to 4 times each year, although 5 monthly
courses of SMC were deployed in South East Senegal and were highly effective and safe [6].
Evaluation of SMC at scale suggests that this intervention has an important impact on
uncomplicated malaria, hospital admissions for malaria, and malaria deaths (the
ACCESS-SMC partnership, submitted) [7–11]. However, despite the benefits of SMC, coun-
tries where SMC is currently deployed include some of the largest contributors to the global
malaria burden, including northern Nigeria, Burkina Faso, and Mali [12]. In these areas of the
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Sahel and sub-Sahel, the malaria burden has remained very high despite scale-up of access to
LLINs, effective artemisinin-based combination therapies (ACTs), and more recently SMC
[12]. In such areas, it is unclear to what extent this represents ‘operational gaps’ in SMC pro-
grammes (e.g., deficiencies in coverage of the monthly courses or adherence to the 3-day
regimen) and to what extent this is a ‘residual burden’ that would remain even if SMC was
deployed under optimal conditions. This is an important distinction because any burden that
would remain in the face of an optimised SMC programme must be tackled by other means.
This could include adding monthly cycles of SMC to cover the burden that occurs outside the
peak transmission season and providing SMC to older children, both of which have been
shown to be effective and safe in Senegal [6,13], and, potentially, seasonally targeted vaccina-
tion to complement the protection from SMC [14].
Another concern that must be carefully monitored is the potential effect of drug resistance.
Parasites resistant to SP or AQ could be at a selective advantage in areas where SMC is used
widely, and this could lead to a reduction in the efficacy of SMC over time. Large-scale surveys
of molecular markers have been conducted in several SMC countries [15]. Case–control stud-
ies have also been used to monitor the in vivo efficacy of SMC directly [16], but a range of
other aspects need to be monitored to fully assess any potential changes in effectiveness.
In this study, data were reanalysed from a large-scale, closely supervised trial of SMC in
southern Burkina Faso and Mali [17]. High coverage and adherence were achieved through
directly observed treatment with SMC. The prevalence of molecular markers of parasite resis-
tance to SP and AQ and the efficacy of the SMC regimen in clearing malaria parasitaemia were
assessed. The high malaria incidence and prevalence in this context show the limitations of
SMC in one of the epidemiological situations that is proving most challenging for malaria
control.
Methods
Study procedures
This analysis uses data collected during the azithromycin (AZ)-SMC study, a household-ran-
domised, placebo-controlled trial conducted in Hounde´ District, Burkina Faso and Bougouni
District, Mali between August 2014 and December 2016 (S1 Fig), undertaken to investigate the
potential value of adding AZ to the antimalarials used for SMC [17]. The primary outcome of
the trial was hospital admissions and deaths; to investigate this outcome, a total sample size of
at least 19,200 children was needed. In July 2014, 19,578 children (i.e., approximately 10,000
per country) aged 3–59 months were recruited through a household census of the study areas
and randomised to intervention group by household. Children with a chronic disease, with
a known allergy to SP, AQ, or AZ, or who were taking cotrimoxazole were not eligible for
inclusion. The study was designed as an open cohort: children born into study households or
who moved into the study area during the study period were eligible to receive SMC if aged
between 3–59 months at the time of the first SMC course in August each year. Following
national guidelines, children aged 60 months or more at the first SMC administration each
year were no longer eligible. Children remained in follow-up until the study ended in Decem-
ber 2016 or the child died or exited the study area, was lost to follow-up, or became too old to
receive SMC.
Between August and November each year, study children received 4 monthly courses of
SMC with SP + AQ, with either AZ or a matching AZ placebo (hereafter SMC plus AZ and
SMC plus placebo, respectively). SMC had not been deployed in the study area prior to the
trial. In 2014, SMC delivery began in late August; in 2015 and 2016, delivery began on the first
of August. Although there was no evidence of a benefit of AZ against all-cause hospitalisations
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and deaths, hospital admissions or deaths due to malaria, or uncomplicated clinical malaria, to
avoid any possible influence of AZ on the results presented in this paper, only children who
were randomised to SMC plus placebo are included. In total, 108,176 courses (321,642 individ-
ual daily doses) of SMC plus placebo were administered as directly observed therapy by the
study team. All doses of study medication were recorded using tablet PCs. Scanning of the
Quick Response (QR) code on the drug package and a child’s photo ID card were used to
ensure linkage of treatment to the correct child, and the date and time stamp of each drug
administration was recorded by the tablet PC.
Morbidity episodes were detected passively throughout the study period at the hospital and
health centres in each study area (S2 and S3 Figs). In Mali, some children were treated by com-
munity health workers, using a rapid diagnostic test (RDT) to confirm Plasmodium falciparum
parasitaemia. The child’s photo ID card was used to ensure that morbidity episodes were
recorded for the correct study child. The following passively detected outcomes were included
in this study: 1) incidence of malaria hospital admissions or deaths from malaria (as a com-
bined outcome), defined as hospital admission for malaria combined with a positive blood
slide or rapid diagnostic test, or deaths for which malaria was listed as the primary diagnosis;
and 2) uncomplicated clinical malaria episodes, defined as history of fever or measured axillary
temperature�37.5 ˚C combined with a positive RDT. Histidine-rich protein 2 (HRP2)-based
RDTs were used to diagnose uncomplicated malaria and to guide treatment. Blood smears
were taken from a systematic sample of study children for quality control of the RDT (slides
were prepared 1 day per week in Burkina Faso and 1 week per month in Mali). All blood
smears, both those used to diagnose malaria in hospital and those used for QC of the RDT,
were double read, with discrepancies resolved by a third reader using a standardised algorithm
[18]. For deaths occurring outside a health facility, verbal autopsies were used to ascertain
cause of death, using the WHO Verbal Autopsy Questionnaire [19]. To assign a final diagnosis,
both the verbal autopsy questionnaires and hospital records were reviewed independently by 2
physicians, with any disagreement reviewed by a third physician. The final diagnosis was
reached by agreement between at least 2 physicians. All diagnoses were assigned prior to lock-
ing of the study database and breaking of the randomisation code. All reviewers were blind to
the study group to which an individual child belonged.
At the end of each rainy season, the prevalence of P. falciparum infection was determined
amongst randomly selected study children at cross-sectional surveys (target sample size of
2,000 per country, 1,000 per randomisation group in each country). Surveys were timed to
occur at least 1 month after the final SMC administration and thus took place later in the first
year of the study because of the later start in 2014. Two infection outcomes were defined: P. fal-
ciparum infection of any density and P. falciparum infection with a density�5,000 per micro-
litre. Blood samples were also taken through school-based surveys from school-age children
resident in the same areas as the study children (500 per country in each year) who were not
eligible to receive SMC because of their age.
The presence of molecular markers of resistance of P. falciparum to SP and AQ was deter-
mined amongst all study children who carried P. falciparum infection at the end-of-season sur-
veys and from 50 school-age children with P. falciparum infection at the same time point.
DNA was extracted from dried blood spots as described previously [20,21] (summarised in S1
Methods).
Each week during the malaria transmission season, P. falciparum prevalence was also deter-
mined amongst a sample of study children who were visited at home (i.e., active case detec-
tion). A target sample size of 100 per week (50 per randomisation group) was used in each
country. Blood smears were taken and read later, so a positive result did not result in the child
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being treated. If a child had symptoms of malaria, they were tested with an RDT and, if posi-
tive, referred for treatment at the health centre.
Ethical approval and consent
The AZ-SMC trial was approved by the ethics committees of the London School of Hygiene
and Tropical Medicine, London (29 May 2013, no. 6355); the Malaria Research and Training
Center, University of Bamako, Bamako, Mali (27 Feb 2014, no. 2014/16/CE/FMPOS); the
Ministry of Health, Ouagadougou, Burkina Faso (20 March 2013, no. 2013-3-023); and the
national regulatory authorities of Burkina Faso and Mali. Written informed consent was
obtained from the parent or guardian of all study children.
Analysis of the incidence of malaria hospital admissions or deaths from
malaria and uncomplicated malaria
Person-time at risk was calculated from the first dose of SMC in 2014 (or from time of entry
into the study for children born in study household or who migrated into the study area) until
the study ended in December 2016 or the child died or exited the study area or became too old
to receive SMC. For children lost to follow-up, the date of the last contact was used. Multiple
events were included. Person-time was not adjusted after a malaria episode [22], but repeat
contacts with healthcare for the same illness within 7 days of a prior episode were considered
as a single event. Lexis expansion was used to stratify person-time for each child on the child’s
current age in years, the calendar month, and the date of each SMC course.
The incidence of 1) malaria hospital admissions or deaths from malaria and 2) uncompli-
cated malaria was calculated by age in the 2 centres combined and by country. The incidence
of these 2 outcomes was also calculated in each calendar month of the study, allowing compar-
ison of periods when SMC was distributed (August–November) with periods when SMC was
not deployed. For uncomplicated clinical malaria, incidence when SMC was deployed was fur-
ther stratified according to whether a child had received SMC in the past 28 days (‘recent
SMC’) or had missed the previous SMC course (‘no recent SMC’). To limit the potential for
confounding by factors related to access to SMC, the incidence rates amongst children with
‘no recent SMC’ in each calendar month was restricted to children who otherwise received all
SMC courses that year (i.e., received the other 3 of the 4 monthly SMC courses).
The detailed SMC history obtained for each child was used to further stratify person-time
at risk according to the number of days since the most recent SMC course (0–7, 8–14, 15–21,
22–28, 28–35, >35 days, and no previous SMC in the current year). Person-time and events
within these strata were then pooled over the study period to calculate incidence rates by time
since SMC. Poisson regression with a gamma-distributed random effect fitted at the household
level was used to calculate incidence rate ratios comparing incidence within the first 28 days
post-SMC with incidence in the period beyond 35 days post-SMC (i.e., beyond the monthly
delivery schedule), accounting for household clustering and adjusting for age of the child in
years.
Analysis of the prevalence of P. falciparum infection
For the end-of-season surveys, the prevalence of P. falciparum infection was calculated for
study children and for school-age children resident in the study areas. Prevalence was also cal-
culated separately for study children who had and had not received SMC at the most recent
round of SMC administration before the survey. Prevalence ratios were calculated comparing
children with and without recent SMC using modified Poisson regression [23], with a robust
standard error to account for household clustering and adjusting for age of the child in years.
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For the weekly surveys during the transmission season, P. falciparum prevalence was calcu-
lated overall and according to receipt (or not) of the most recent round of SMC administration
prior to the weekly survey. As for the end-of-season surveys, prevalence ratios were calculated
comparing children with and without recent SMC using modified Poisson regression [23],
with a robust standard error to account for the household-randomised design and adjusting
for age of the child in years.
Analysis of the frequency and prevalence of molecular markers of SP and
AQ resistance
The frequency and prevalence of resistant mutants were calculated as 1) the number of resis-
tant mutants/the total number of clones and 2) the number of resistant mutants/the number of
study children, respectively (further details are provided in S1 Methods). For prevalence, infec-
tions carrying mixed mutations at a single locus were counted as resistant. Samples for which 2
or more codons had both mutant and wild type present were excluded from the analysis.
Analysis of the treatment efficacy of SP + AQ
At the end of the study period, after 3 years of SMC deployment in each of the study areas, a
treatment efficacy study was undertaken amongst children with asymptomatic P. falciparum
infection at the final cross-sectional survey. Children with no symptoms of malaria with a posi-
tive RDT, subsequently confirmed by microscopy, were eligible for this study. Fifty-eight and
153 children were included in Burkina Faso and Mali, respectively. These children received a
full treatment course of SP + AQ over 3 days, dosed according to age, i.e., the same regimen as
used for SMC. Children were then followed for 28 days according to a standard treatment effi-
cacy protocol, with parasitaemia and symptoms assessed at days 1, 2, 4, 7, 14, 21, and 28 after
treatment. Infections after day 7 (late parasitological failures) were investigated to determine
whether the infection was caused by a recrudescence or by reinfection. DNA extracted from
dried blood spots using a previously published method (described in the S1 Methods) were
used for molecular analyses of msp1, msp2, and CA1 polymorphisms to distinguish recrudes-
cent from new infections. Cases of post-treatment mixed infection that contained parasites
from day 0 were counted as recrudescent. Change of profile in any or both loci was counted as
reinfection. Adequate clinical and parasitological response (ACPR) rates were recalculated
both unadjusted for reinfection and adjusted for reinfection by limiting the cases of failure to
true recrudescent parasites [24].
Statistical analysis plan
Analysis of the frequency and prevalence of molecular markers of SP and AQ resistance
amongst study children and school-age children and the treatment efficacy of SP plus AQ
amongst children with asymptomatic P. falciparum infection were prespecified in the statistical
analysis plan for the main trial [17]. Analyses of malaria incidence by age, by calendar time,
and by time since the most recent SMC administration and analysis of prevalence according to
the time since most recent SMC administration were not included in the trial’s statistical anal-
ysis plan, but these secondary analyses were planned prior to breaking the study randomisa-
tion code, and the locked databases were used for all analyses.
Results
In the first year of the study (August 2014–July 2015), 9,603 children were under observation
in the placebo group. The cohort under observation grew to 10,760 and 11,047 children in the
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second and third years, respectively, with similar numbers in each country throughout the
study. Demographic information is presented in Table 1. The cohort was approximately 51%
male throughout the study period and increased slightly in age in successive years (mean age
2.01 in year 1, 2.14 in year 2, and 2.17 in year 3). LLIN use was high in both countries prior to
enrolment (72.4% in Burkina Faso and 72.7% in Mali), after which all children received a new
LLIN from the study team.
Table 1. Characteristics of children in follow-up in each year of the study.
Burkina Faso Mali Both Centres
No. % No. % No. %
Follow-up in Study Year 1 (2014)
Number of children in placebo group 4,758 4,845 9,603
Age in years on August 1st, 2014
0 909 19.1 830 17.1 1,739 18.1
1 1,013 21.3 991 20.5 2,004 20.9
2 960 20.2 1,084 22.4 2,044 21.3
3 966 20.3 1,061 21.9 2,027 21.1
4 910 19.1 879 18.1 1,789 18.6
Mean age in years (SD) 1.99 1.39 2.03 1.35 2.01 1.37
Sex
Male 2,471 51.9 2,462 50.8 4,933 51.4
LLIN use prior to study�
yes 3,428 72.4 3,305 72.7 6,733 72.5
missing 26 296 322
Follow-up in Study Year 2 (2015)
Number of children in placebo group 5,324 5,436 10,760
Age in years on August 1st, 2015
0 805 15.1 703 12.9 1,508 14
1 1,165 21.9 1,156 21.3 2,321 21.6
2 1,166 21.9 1,203 22.1 2,369 22
3 1,090 20.5 1,240 22.8 2,330 21.7
4 1,098 20.6 1,134 20.9 2,232 20.7
Mean age in years (SD) 2.10 1.36 2.17 1.33 2.14 1.34
Sex
Male 2,761 51.9 2,742 50.5 5,503 51.2
Follow-up in Study Year 3 (2016)
Number of children in placebo group 5,423 5,624 11,047
Age in years on August 1st, 2016
0 751 13.8 805 14.3 1,556 14.1
1 1,120 20.7 1,078 19.2 2,198 19.9
2 1,208 22.3 1,261 22.4 2,469 22.3
3 1,212 22.3 1,232 21.9 2,444 22.1
4 1,132 20.9 1,248 22.2 2,380 21.5
Mean age in years (SD) 2.16 1.34 2.18 1.36 2.17 1.35
Sex
Male 2,842 52.4 2,864 51 5,706 51.7
�Information on LLIN use was only collected in 2014 because all children were issued with a new LLIN upon enrolment. Abbreviations: LLIN, long-lasting insecticide-
treated net.
https://doi.org/10.1371/journal.pmed.1003214.t001
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Adherence to the monthly SMC schedule and 3-day SMC regimen were high in both coun-
tries (S1 Table and S2 Table). The percentage of study children receiving all 4 monthly courses
of SMC ranged from 64.9% to 75.4% in Burkina Faso and between 61.6% and 74.3% in Mali.
The percentage of study children who received at least 3 cycles was 86.0% to 93.8% in Burkina
Faso and 82.3% to 91.1% in Mali. Amongst children receiving the first dose of each cycle, the
number who received all 3 daily doses ranged from 94.7% to 99.9% in Burkina Faso and 91.2%
to 99.3% in Mali.
Incidence of malaria hospital admissions or deaths from malaria and
uncomplicated clinical malaria
In total, 23,817.2 person-years of follow-up were recorded amongst children in the SMC plus
placebo group (11,772.3 and 12,042.6 person-years in Burkina Faso and Mali, respectively).
One hundred thirty-five nonfatal malaria hospital admissions, 28 deaths from malaria, and
10,329 uncomplicated clinical malaria episodes occurred amongst children in the SMC plus
placebo group in Burkina Faso; the corresponding number of these events were 109, 26, and
10,419, respectively, in children randomised to SMC plus placebo in Mali. The overall inci-
dence of malaria hospital admissions or death from malaria and uncomplicated malaria was
12.5 (95% confidence interval [CI]: 11.2, 14.1) and 871.1 (95% CI: 852.3, 890.6) cases per 1,000
child-years at risk, respectively. The rates were slightly higher in Burkina Faso: 13.8 (95% CI:
11.9, 16.2) malaria hospital admissions or deaths from malaria and 877.4 (95% CI: 852.3,
903.5) uncomplicated malaria episodes per 1,000 person-years at risk, whereas in Mali, the cor-
responding rates were 11.2 (95% CI: 9.45, 13.4) and 865.2 (95% CI: 837.4, 894.3) per 1,000 per-
son-years. Amongst 2,626 episodes of uncomplicated malaria for which a blood smear was
available in addition to the RDT result, 31.3% (95% CI: 28.9%, 33.8%) were slide-negative in
Burkina Faso and 31.3% (95% CI: 28.4%, 34.4%) in Mali.
Incidence of both hospital admissions and deaths from malaria and uncomplicated malaria
peaked in children 2 years of age in both countries (Fig 1). Malaria deaths specifically peaked
in infancy in Burkina Faso and in 1- and 2-year old children in Mali, although the number of
deaths in each year of age were low, and thus, CIs are wide (S4 Fig).
Analysis by calendar month. In each year of the study, both malaria hospitalisations and
deaths from malaria (Fig 2a) and uncomplicated clinical malaria (Fig 2b) peaked in July, prior
to delivery of the first SMC course in August. During the rainy season, when SMC was given,
the incidence of malaria hospitalisations and deaths from malaria remained slightly higher
than during the dry season period but was markedly lower than the incidence immediately
before SMC delivery began. Despite high SMC coverage, the overall incidence of uncompli-
cated malaria diagnosed by RDT was still 100 cases per 1,000 child-months during the rainy
season. During the peak transmission period, the incidence of uncomplicated clinical malaria
was very low amongst children with recent receipt of SMC, whereas children without recent
SMC had a much higher incidence (Fig 2c). These results were similar in the 2 study sites (S5
and S6 Figs), with a slightly higher incidence in Burkina Faso.
Analysis by time since SMC. The incidence of malaria hospitalisations and deaths from
malaria was 13.6 per 1,000 child-years at risk (95% CI: 11.2, 16.8) in the first 28 days after SMC
treatment (Fig 3a) but increased markedly beyond this time period to 51.1 per 1,000 child-
years (95% CI: 42.1, 62.7). The incidence rate ratio comparing SMC within the past 28 days to
SMC more than 35 days ago (i.e., not adherent to the monthly schedule) was 0.13 (95% CI:
0.08, 0.20), P< 0.001, indicating a protective efficacy of 87.4% (95% CI: 79.6%, 92.2%).
A similar pattern was observed for the incidence of uncomplicated clinical malaria (Fig 3b),
with a low incidence rate in the first 3 weeks after SMC (402.1 [95% CI: 383.5, 421.9] overall in
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Fig 1. Incidence of malaria hospital admissions and deaths from malaria and clinical malaria by age. Incidence of
malaria hospitalisations and deaths from malaria (left panel) and uncomplicated clinical malaria (right panel) by age
group over the study period. Malaria hospitalisations and deaths from malaria were defined as hospital admission with
a diagnosis of malaria and blood-slide–or RDT-confirmed P. falciparum infection or deaths for which malaria was
listed as the primary diagnosis. Clinical malaria was defined as attendance at study health facility with a history of fever
or measured temperature�37.5 ˚C, with malaria infection confirmed by RDT. Incidence rates are presented per 1,000
person-years and include repeat events in the same child, provided the healthcare contact occurred more than 7 days
apart. Vertical bars show 95% CIs. CI, confidence interval; RDT, rapid diagnostic test.
https://doi.org/10.1371/journal.pmed.1003214.g001
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Fig 2. The incidence of malaria hospitalisations and deaths from malaria and uncomplicated clinical malaria over the study
period by month of year. Incidence of malaria hospitalisations and deaths from malaria (a) and clinical malaria (b) by calendar
month over the study period. (c) shows the incidence of uncomplicated malaria during the period when SMC was delivered
(shown by vertical dashed lines) amongst children who had received SMC within the previous 28 days or who had not received
recent SMC (no SMC in the previous 35 days). Incidence rates are presented as per 1,000 person-months at risk rather than per
1,000 person-years and include repeat events in the same child, provided the healthcare contact occurred more than 7 days apart.
Vertical bars show 95% CIs. The analysis of children with ‘no recent SMC’ was restricted to children who received 3 courses of
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SMC during that intervention year (i.e., this excludes children who missed SMC on more than one occasion). Malaria
hospitalisations and deaths from malaria were defined as hospital admission with a diagnosis of malaria and blood-slide–or
RDT-confirmed P. falciparum infection or deaths for which malaria was listed as the primary diagnosis. Clinical malaria was
defined as attendance at study health facility with a history of fever or measured temperature�37.5 ˚C, with malaria infection
confirmed by RDT. CI, confidence interval; RDT, rapid diagnostic test; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1003214.g002
Fig 3. The incidence of malaria hospitalisations and deaths from malaria and episodes of uncomplicated
clinical malaria by time since the most recent SMC treatment. Incidence of malaria hospitalisations and deaths
from malaria (a) and clinical malaria (b) according to time since the most recent SMC course. Incidence rates are
presented per 1,000 person-years at risk. Vertical bars show 95% CIs. ‘No SMC this year’ indicates children who had
not yet received their first course of SMC in that year of the study (but who subsequently received SMC). Malaria
hospitalisations and deaths from malaria were defined as hospital admission with a diagnosis of malaria and blood-
slide–or RDT-confirmed P. falciparum infection or deaths for which malaria was listed as the primary diagnosis.
Clinical malaria was defined as attendance at study health facility with a history of fever or measured temperature
�37.5 ˚C, with malaria infection confirmed by RDT. CI, confidence interval; RDT, rapid diagnostic test; SMC,
seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1003214.g003
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the first 21 days). This increased to 908.4 cases per 1,000 child-years (95% CI: 862.3, 957.7)
between 22 to 28 days since last receipt of SMC and then exceeded 2,500 cases per 1,000 child-
years at risk from 29 days post-SMC onwards. The incidence rate ratio comparing SMC within
the past 28 days to SMC more than 35 days ago was 0.21 (95% CI 0.20, 0.23), P < 0.001, indi-
cating a protective efficacy of 78.3% (95% CI: 76.8%, 79.6%).
Prevalence of P. falciparum at cross-sectional surveys
End-of-season surveys. The overall prevalence of P. falciparum amongst study children
was below 10% at all 3 end-of-season cross-sectional surveys in both countries (Table 2). Infec-
tions with parasite density in excess of 5,000 per microlitre were found in less than 5% of study
children in all but one survey (Mali, 2015, in which prevalence was 6.2%). Compared with chil-
dren who had received the most recent SMC course, prevalence was markedly higher amongst
study children who had missed the most recent SMC prior to the cross-sectional survey: the
smallest prevalence ratio was 3.02 (95% CI: 1.98, 4.60), P < 0.001. Prevalence ratios remained
comparable when children who missed the most recent SMC course were restricted to those
who had otherwise received all SMC courses that year (S3 Table). Amongst school-age chil-
dren, who were not eligible for SMC, the prevalence of P. falciparum parasitaemia of any den-
sity was above 50% in all 3 cross-sectional surveys in both countries.
Table 2. P. falciparum parasitaemia at the end of the malaria transmission season surveys amongst study children in the placebo group and in school-age children.
All Children Children Who Received
Final SMC Cycle before the
Survey
Children Who Missed the
Final SMC Cycle before the
Survey
Any parasitaemia Parasitaemia �5,000/μl Any parasitaemia Any parasitaemia
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) Prevalence ratio� (95% CI) P-value
Burkina Faso
Study Children (SMC plus Placebo Group)
2014 27/1,009 2.68 (1.84, 3.88) 5/1,009 0.50 (0.21, 1.19) 20/976 2.05 (1.33, 3.16) 7/33 21.2 (10.4, 38.3) 11.8 (5.68, 24.5) <0.001
2015 97/983 9.87 (8.16, 11.9) 48/983 4.88 (3.68, 6.44) 77/920 8.37 (6.74, 10.4) 20/63 31.7 (21.5, 44.2) 3.60 (2.30, 5.63) <0.001
2016 83/973 8.53 (6.90, 10.5) 35/973 3.60 (2.60, 4.96) 64/909 7.04 (5.51, 8.95) 19/64 29.7 (19.6, 42.2) 4.07 (2.57, 6.45) <0.001
School-Age Children
2014 308/497 62.0 (57.6, 66.1) 23/497 4.63 (3.09, 6.87)
2015 324/529 61.2 (57.0, 65.3) 29/529 5.48 (3.83, 7.78)
2016 251/500 50.2 (45.8, 54.6) 28/500 5.60 (3.89, 8.00)
Mali
Study Children (SMC plus Placebo Group)
2014 57/988 5.77 (4.44, 7.47) 27/988 2.73 (1.89, 3.94) 49/950 5.16 (3.91, 6.78) 8/38 21.1 (10.4, 38.1) 4.80 (2.36, 9.76) <0.001
2015 90/983 9.16 (7.46, 11.2) 61/983 6.21 (4.85, 7.92) 47/861 5.46 (4.13, 7.19) 36/109 33.0 (24.3, 43.2) 5.61 (3.77, 8.33) <0.001
2016 90/1,009 8.92 (7.28, 10.9) 28/1,009 2.78 (1.95, 3.94) 67/906 7.40 (5.83, 9.34) 23/103 22.3 (15.4, 31.2) 2.98 (1.95, 4.54) <0.001
School-Age Children
2014 294/496 59.3 (54.9, 63.5) 31/496 6.25 (4.43, 8.76)
2015 326/500 65.2 (60.9, 69.3) 47/500 9.40 (7.13, 12.3)
2016 268/500 53.6 (49.2, 57.9) 26/500 5.20 (3.56, 7.53)
Prevalence of P. falciparum parasitaemia at the end-of-season cross-sectional survey (carried out at least 1 month after the last SMC cycle in each year). The table shows
infection of any density and density�5,000 per microlitre overall amongst study children in the SMC plus placebo group and according to receipt of SMC at the most
recent delivery cycle. Abbreviations: CI, confidence interval; SMC, seasonal malaria chemoprevention.
�Prevalence ratios compare children who received the final SMC before the survey and who missed the final SMC course and adjust for age and household-level
clustering. Prevalence amongst school-age children resident in the study area (data from Chandramohan and colleagues [17]) is included for comparative purposes.
https://doi.org/10.1371/journal.pmed.1003214.t002
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Weekly surveys during the transmission season. Prevalence of P. falciparum parasitae-
mia at the weekly surveys (Table 3) was generally lower than at the end-of-season surveys
because most children were protected by SMC at the time of sampling, and prevalence was
below 10% in all 3 years in both countries. As was the case for the end-of-season surveys, chil-
dren who had not received SMC in the past 28 days at the time of the weekly survey were at a
much higher risk of carrying infection than those who had: the smallest prevalence ratio
observed was 4.32 (95% CI: 2.46, 7.58), P< 0.001).
Molecular markers of resistance to SP and AQ
The frequency of molecular markers associated with AQ resistance (P. falciparum chloroquine
resistance transporter, pfcrt K76T; P. falciparum multidrug resistance 1, pfmdr1 N86Y; and the
combined pfcrt K76T + pfmdr1 N86Y haplotype) did not increase amongst study children
between 2014 and 2016 (Table 4). Likewise, the frequency of molecular markers associated
with both pyrimethamine resistance (P. falciparum dihydrofolate reductase, pfdhfr-C59R) and
sulfadoxine resistance (P. falciparum dihydropteroate synthase, pfdhps-A437G and pfdhps-
K540E) did not increase over the study period. In particular, the pfdhps-K540E mutation, asso-
ciated with high-grade resistance to sulfadoxine, remained at low frequency, with just 8 out of
254 samples resistant in 2016. Similar results were observed by country or when the prevalence
of resistance markers amongst study children was calculated (S4 Table).
The frequency of these resistance markers amongst school-age children not eligible for
SMC but resident in the study area and thus exposed to the same circulating parasites was
comparable with the frequency of mutations amongst parasites obtained from study children
(Table 5). The combined pfcrt K76T + pfmdr1 N86Y haplotype remained rare at the end of the
study period, and the pfdhps-K540E mutation also remained at low frequency, with only 5 of
146 samples positive for this mutation in 2016.
In vivo treatment efficacy of SP + AQ
Two hundred and eleven study children (58 in Burkina Faso, 153 in Mali) with asymptomatic
P. falciparum infection at the final end-of-season survey in 2016 were recruited and treated
Table 3. Malaria parasitaemia at the weekly surveys in the SMC plus placebo group.
All Children SMC in Past 28 Days No SMC in Past 28 Days
Any parasitaemia Parasitaemia�5,000/μl Any parasitaemia Any parasitaemia
n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) Prevalence ratio� (95% CI) P-value
Burkina Faso
2014 43/863 4.98 (3.71, 6.65) 15/863 1.74 (1.05, 2.86) 15/685 2.19 (1.32, 3.61) 28/177 15.8 (11.1, 22.0) 7.29 (3.96, 13.4) <0.001
2015 59/792 7.45 (5.80, 9.53) 30/792 3.79 (2.66, 5.36) 26/618 4.21 (2.88, 6.11) 33/171 19.3 (14.0, 25.9) 4.47 (2.77, 7.22) <0.001
2016 43/837 5.14 (3.81, 6.90) 19/951 2.00 (1.25, 3.18) 19/690 2.75 (1.72, 4.38) 24/146 16.4 (11.3, 23.3) 5.56 (3.09, 9.98) <0.001
Mali
2014 6/644 0.93 (0.42, 2.06) 2/644 0.31 (0.08, 1.24) 1/505 0.20 (0.03, 1.40) 5/139 3.60 (1.50, 8.39) 18.5 (2.31, 148.1) 0.006
2015 48/771 6.23 (4.73, 8.16) 22/771 2.85 (1.89, 4.29) 21/611 3.44 (2.26, 5.20) 23/155 14.8 (10.0, 21.4) 4.07 (2.31, 7.15) <0.001
2016 38/761 4.99 (3.68, 6.75) 19/850 2.24 (1.44, 3.46) 13/579 2.25 (1.31, 3.83) 25/181 13.8 (9.52, 19.6) 6.42 (3.38, 12.2) <0.001
Prevalence of P. falciparum parasitaemia at weekly survey contacts during the malaria transmission season (i.e., between the first SMC cycle in each year and 1 month
after the final SMC cycle). The table shows P. falciparum infection of any density and density�5,000 per microlitre amongst study children overall and according to
whether the child received SMC at the most recent delivery cycle prior to the survey. Abbreviations: CI, confidence interval; SMC, seasonal malaria chemoprevention.
�Prevalence ratios compare children who had received SMC within the past 28 days and those with no SMC in the past 28 days and adjust for age and household-level
clustering.
https://doi.org/10.1371/journal.pmed.1003214.t003
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with SP + AQ. Their age ranged from 7 to 63 months (including 4 children under 60 months
in August 2016 and thus eligible for SMC who had since reached 5 years of age). Two children
experienced early treatment failure, one in each country (S5 Table). In both cases, the child
had a higher parasite density on day 2 than on day 0, although the densities were low in each
case, and neither child was febrile (62 versus 48 parasites per microlitre in the child seen in
Burkina Faso; 490 and 170 per microlitre in the child seen in Mali). There were no late parasi-
tological failures (no asexual-stage parasitaemia) in Burkina Faso. There were 5 reinfections
but no recrudescences in Mali. The unadjusted ACPR, including reinfections, was 98.3% (95%
CI: 88.6%, 99.8%) in Burkina Faso and 96.1% (95% CI: 91.5%, 98.2%) in Mali. When reinfec-
tions were excluded, the ACPR rose to 99.3% (95% CI: 95.4%, 99.9%) in Mali.
Discussion
Despite the very high level of malaria transmission in the 2 study districts, SMC appeared to
provide a high level of protection against both malaria hospitalisations and deaths from
malaria and uncomplicated clinical malaria; this was demonstrated by 3 key findings. Firstly,
the incidence of malaria hospitalisations and deaths from malaria and episodes of uncompli-
cated clinical malaria was markedly lower during the SMC period (August to November) than
in the month immediately preceding it, with evidence that children who received SMC in a
particular month were very well protected. Secondly, incidence of malaria hospitalisations and
deaths from malaria and clinical malaria was substantially lower during the first 4 weeks after
Table 4. Frequency of molecular markers of SP and AQ resistance amongst study children in the placebo group overall and by study country.
Overall Burkina Faso Mali
Mutation n/N Frequency, % (95% CI) n/N Frequency, % (95% CI) n/N Frequency, % (95% CI)
2014
pfcrt K76T 70/110 63.6 (54.5, 71.9) 15/36 41.7 (28.5, 56.2) 55/74 74.3 (63.1, 83.0)
pfmdr1 N86Y 23/110 20.9 (14.6, 29.0) 8/36 22.2 (10.6, 40.9) 15/74 20.3 (13.4, 29.4)
pfcrt K76T + pfmdr1 N86Y 17/110 15.5 (10.2, 22.7) 4/36 11.1 (4.22, 26.2) 13/74 17.6 (11.2, 26.6)
pfdhfr C59R 73/99 73.7 (63.3, 82.0) 29/33 87.9 (67.3, 96.2) 44/66 66.7 (53.7, 77.5)
pfdhps A437G 73/99 73.7 (64.6, 81.2) 23/33 69.7 (51.0, 83.6) 50/66 75.8 (65.3, 83.8)
pfdhps K540E 2/99 2.02 (0.50, 7.79) 1/33 3.03 (0.42, 19.0) 1/66 1.52 (0.20, 10.4)
pfdhfr + pfdhps-437 57/99 57.6 (48.3, 66.4) 21/33 63.6 (44.9, 79.0) 36/66 54.5 (43.7, 65.0)
pfdhfr + pfdhps-437 + pfdhps-540 0/99 0 0/33 0 0/66 0
2016
pfcrt K76T 53/119 44.5 (35.2, 54.2) 7/59 11.9 (5.82, 22.7) 46/60 76.7 (65.0, 85.3)
pfmdr1 N86Y 19/119 16.0 (10.6, 23.3) 8/59 13.6 (6.84, 25.1) 11/60 18.3 (10.8, 29.4)
pfcrt K76T + pfmdr1 N86Y 10/119 8.40 (4.66, 14.7) 0/59 0 10/60 16.7 (9.55, 27.5)
pfdhfr C59R 115/130 88.5 (81.8, 92.9) 61/64 95.3 (86.7, 98.4) 54/66 81.8 (71.1, 89.2)
pfdhps A437G 104/130 80.0 (73.0, 85.5) 51/64 79.7 (70.4, 86.6) 53/66 80.3 (69.0, 88.2)
pfdhps K540E 4/130 3.08 (0.92, 9.75) 2/64 3.13 (0.43, 19.5) 2/66 3.03 (0.74, 11.5)
pfdhfr + pfdhps-437 91/130 70.0 (63.4, 75.8) 48/64 75.0 (66.3, 82.1) 43/66 65.2 (55.1, 74.0)
pfdhfr + pfdhps-437 + pfdhps-540 3/130 2.31 (0.75, 6.91) 1/64 1.56 (0.22, 10.4) 2/66 3.03 (0.74, 11.5)
Frequency of SP and AQ resistance mutations amongst study children with P. falciparum infection at the end-of-season cross-sectional surveys. When both wild-type
and resistant mutants were present at a single codon, it was assumed that 2 clones were present, and both resistant mutants and wild-type clones were counted. The
frequency of the mutation was then calculated as number of resistant mutants/total number of clones. Samples for which 2 or more codons had both mutant and wild
type present were excluded. Abbreviations: AQ, amodiaquine; CI, confidence interval; pfcrt, P. falciparum chloroquine resistance transporter; pfdhfr, P. falciparum
dihydrofolate reductase; pfdhps, P. falciparum dihydropteroate synthase; pfmdr1, P. falciparum multidrug resistance 1; SP, sulfadoxine-pyrimethamine.
https://doi.org/10.1371/journal.pmed.1003214.t004
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an SMC course than in subsequent time periods. The rate ratios obtained and the profile of
protection over time were compatible with results in earlier trials and with observational stud-
ies [25]. Thirdly, the prevalence of P. falciparum was markedly lower in children with recent
SMC at both the end-of-season surveys and the weekly surveys carried out during the rainy
season. The remaining burden amongst study children therefore reflects the exceptionally high
infection rates to which study children were exposed, illustrated by a prevalence of P. falcipa-
rum parasitaemia in excess of 50% amongst school-age children resident in the same areas.
The observed high level of protection from SMC against malaria is compatible with the cur-
rent low prevalence of key molecular markers of SP and AQ resistance observed in the cross-
sectional surveys, the very high curative efficacy of the SMC drug combination in treatment,
and results from other studies that have evaluated SMC in the Sahel region during the period
of the trial [15]. A series of case–control studies conducted as part of the ACCESS-SMC pro-
gramme in 5 countries, including Burkina Faso and Mali, compared children with and without
recent SMC (i.e., similar to the comparisons done prospectively in the present analysis). The
case–control approach found evidence of a high level of protection for the first 28 days after
administration [16], comparable with that seen here, and with previous SMC trials [1,2].
Taken together, these results suggest that SMC should continue to be a priority intervention
for malaria control in areas of intense seasonal transmission. Implementation should be sup-
ported in appropriate epidemiological situations in which it is not yet deployed, and coverage
should be maximised when SMC is already in place. The results from children prior to receipt
Table 5. Frequency of molecular markers of SP and AQ resistance in schoolchildren—2014 and 2016.
Burkina Faso Mali
Mutation n/N Frequency, % (95% CI) n/N Frequency, % (95% CI)
2014
pfcrt K76T 9/66 13.6 (7.23, 24.2) 75/164 45.7 (38.2, 53.4)
pfmdr1 N86Y 13/66 19.7 (11.8, 31.1) 9/165 5.45 (2.85, 10.2)
pfcrt K76T + pfmdr1 N86Y 0/66 0 4/164 2.44 (0.91, 6.35)
pfdhfr C59R 74/79 93.7 (85.6, 97.4) 175/179 97.8 (94.2, 99.2)
pfdhps A437G 31/79 39.2 (29.1, 50.4) 72/179 40.2 (33.3, 47.6)
pfdhps K540E 2/79 2.53 (0.63, 9.62) 0/179 0
pfdhfr + pfdhps-437 30/79 38.0 (27.9, 49.1) 70/179 39.1 (32.2, 46.5)
pfdhfr + pfdhps-437 + pfdhps-540 1/79 1.27 (0.18, 8.51) 0/179 0
2016
pfcrt K76T 7/61 11.5 (5.52, 22.3) 28/51 54.9 (41.1, 68.0)
pfmdr1 N86Y 6/61 9.84 (4.45, 20.4) 6/52 11.5 (5.23, 23.6)
pfcrt K76T + pfmdr1 N86Y 0/61 0 3/51 5.88 (1.89, 16.9)
pfdhfr C59R 68/73 93.2 (84.5, 97.1) 63/72 87.5 (77.6, 93.4)
pfdhps A437G 38/74 51.4 (40.0, 62.6) 27/70 38.6 (27.9, 50.5)
pfdhps K540E 3/74 4.05 (1.30, 11.9) 2/72 2.78 (0.69, 10.5)
pfdhfr + pfdhps-437 36/73 49.3 (38.0, 60.7) 26/70 37.1 (26.6, 49.1)
pfdhfr + pfdhps-437 + pfdhps-540 1/73 1.37 (0.19, 9.23) 1/70 1.43 (0.20, 9.60)
Frequency of SP and AQ resistance mutations amongst school-age children, resident in the study areas, with P. falciparum infection at the end-of-season surveys. When
both wild-type and resistant mutants were present at a single codon, it was assumed that 2 clones were present, and both resistant mutants and wild-type clones were
counted. The frequency of the mutation was then calculated as number of resistant mutants/total number of clones. Samples in which both mutant and wild type were
detected at 2 or more codons were excluded. Abbreviations: AQ, amodiaquine; CI, confidence interval; pfcrt, P. falciparum chloroquine resistance transporter; pfdhfr, P.
falciparum dihydrofolate reductase; pfdhps, P. falciparum dihydropteroate synthase; pfmdr1, P. falciparum multidrug resistance 1; SP, sulfadoxine-pyrimethamine.
https://doi.org/10.1371/journal.pmed.1003214.t005
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of SMC or who missed SMC during the intervention period indicate that there could be a
major increase in burden in the areas identified as a current priority by WHO [12] if SMC pro-
grammes are not supported. The high incidence in children who miss SMC in a particular
month underscores the importance of coverage of all monthly courses for full protection and
the value of this as a target for programme evaluation [26].
Strengths of this study include the large sample size, the careful documentation of all SMC
courses (and daily doses) and morbidity episodes, and the use of tablet PCs (specifically, the
use of QR codes and time/date stamps) to link all contacts to the correct child with a very
high degree of accuracy. Because the main trial was powered to investigate hospital admissions
and mortality as a primary outcome, these analyses have high statistical power to investigate
uncomplicated malaria and severe malaria by time since SMC in more detail than has been
possible in previous (smaller) trials.
However, there are a number of limitations to this study. Given the large scale of the study
and the need to manage children who were unwell promptly, it was not possible for blood
smears to be prepared for all suspected malaria cases. The subset of children for which both an
RDT and blood smear were available indicate that around a third of children positive by RDT
may no longer carry parasites; this was similar in both countries. Low specificity is likely to be
a consequence of parasite antigens remaining in the circulation of children whose infection
has been cleared by SMC or treatment, as observed in a previous SMC study in Senegal [6].
Overdiagnosis is likely to be a feature of most programmatic data because diagnosis of
malaria in the routine system relies on the use of RDTs. However, even if the burden observed
in this study were to be discounted to account for potential overdiagnosis, it would remain
substantial.
Deaths that occurred in the community were diagnosed by verbal autopsy, and thus parasi-
tological confirmation of malaria was not usually possible. Comparison of the intervention
effect over the study period is made difficult by the variability in transmission intensity each
year in these and similar study areas and by the differences in the timing of SMC and end-of-
season surveys (almost a month later in 2014 than in 2015 and 2016). In the analyses of malaria
incidence, children with and without recent SMC were compared, but since children without
SMC in a particular month were those who missed their scheduled SMC, this was not a ran-
domly allocated exposure. It is possible that children with poor SMC coverage live in more
remote parts of the community and have higher malaria risk. When comparing children on
the basis of their adherence to SMC, the analysis strategy attempted to minimise confounding
through this mechanism by including only those children who received at least 3 of the 4
scheduled SMC courses in that calendar year (i.e., children who missed a particular SMC
course received all other courses that year).
Prevalence ratios were calculated as a simple way to show the large differences in carriage of
parasites between those with and without SMC. However, the specific values of the prevalence
ratios may not be widely generalisable (e.g., the prevalence ratio of 11.8 observed in 2014 in
Burkina Faso could not apply in areas with prevalence amongst SMC recipients in excess of
8.5% because prevalence is constrained between 0% and 100%).
Although the prevalence of resistance markers was low in 2014 and in 2016, it will be
important to monitor longer-term changes on molecular markers of resistance. The timing of
the treatment efficacy study towards the end of the malaria transmission season is likely to
have limited the number of reinfections to which study children were exposed. It is also
unclear whether curative efficacy would differ in children with higher-density infections,
although these children would be more likely to have symptoms and thus be treated with arte-
mether-lumefantrine, the first-line treatment regimen in both study areas, rather than SMC.
PLOS MEDICINE Seasonal malaria chemoprevention in Hounde´ District, Burkina Faso and Bougouni District, Mali
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003214 August 21, 2020 17 / 23
Despite the positive findings with respect to the benefit of SMC in the study areas, these
results show that more must be done to protect young children from the consequences of
malaria in areas of intense seasonal transmission. It is clear that missed SMC courses result in
a markedly elevated risk of both uncomplicated and malaria hospitalisations and deaths from
malaria, and thus, it is important to ensure that delivery reaches as many children as possible
each month. This may require a mixture of delivery strategies (e.g., door-to-door delivery with
fixed points available if these contacts are missed).
Our findings indicate that 4 courses of SMC are not sufficient to cover the entire malaria
transmission season in the southern part of Burkina Faso and Mali, where rainfall peaks over a
longer period than in the northern parts of the Sahel region. In each year of the study, a large
number of cases of uncomplicated malaria, malaria hospitalisation, and deaths from malaria
were recorded in July, prior to SMC delivery in August. Providing additional SMC courses
may, therefore, have an important impact on the malaria burden. SMC programmes using 5
or 6 courses should be evaluated in these areas and other areas at similar latitudes, such as
northern Ghana, that have similar epidemiology [27,28] and large populations at risk. Addi-
tional SMC courses could help mitigate against the risks of introducing drug resistance by
helping to avoid situations in which either SMC begins too late, and thus SP and AQ are used
to clear high-density infections from a large proportion of children [29], or SMC finishes too
soon, leaving children exposed to reinfection when the residual concentrations of SMC drugs
have fallen below therapeutic levels.
Additional interventions are also needed to reduce the malaria risk when SMC courses are
inevitably missed. Seasonal vaccination with a malaria vaccine [14] may be one approach, and
the RTS,S/AS01 malaria vaccine is currently being evaluated as an addition to SMC in the
study districts (clinicaltrials.gov NCT03143218). However, unless these approaches are
strongly synergistic, it is likely that even further interventions will be needed, such as addi-
tional methods of vector control, for these areas where malaria has proved most challenging to
control and continues to overload the health system.
In summary, SMC remains highly protective in the trial areas, and our results emphasise
the need for continued support of SMC programmes. However, the high incidence of malaria
in July each year emphasises the need for a fifth monthly course of SMC to adequately cover
the whole transmission season. Additional measures beyond SMC and LLINs are needed to
further reduce malaria burden in these areas and areas with similar epidemiology.
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